Short-term cost-effectiveness analysis of tirzepatide for the treatment of type 2 diabetes in the United States

作者
Xiaotong Zhang,Carrie McAdam Marx
出处
期刊:Journal of managed care & specialty pharmacy [AMCP]
卷期号:29 (3): 276-284 被引量:21
标识
DOI:10.18553/jmcp.2023.29.3.276
摘要

BACKGROUND: Tirzepatide is a novel once-a-week dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist that is used as an addition to diet and exercise to improve blood glucose in adults with type 2 diabetes. It is the first dual glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor agonist that has been approved by the US Food and Drug Administration. The SURPASS-2 clinical trial demonstrated superiority of tirzepatide 10 mg and 15 mg over semaglutide 1 mg in glycated hemoglobin A1c reduction and weight loss from baseline to week 40. Economic analyses to support coverage and access decision-making for tirzepatide are limited. OBJECTIVES: To evaluate the cost-effectiveness of tirzepatide 10 mg vs semaglutide 1 mg injection over 52 weeks of treatment regarding A1c reduction and weight loss from the perspective of the US health care payer. METHODS: A decision tree model over a 52-week time horizon was developed to identify incremental treatment-related costs of once-weekly tirzepatide 10 mg vs semaglutide 1 mg injection. Costs were divided by mean reduction in A1c and change in body weight from baseline to week 52 observed in the SURPASS-2 clinical trial. In addition to efficacy, probabilities of adverse events, discontinuation, and need for rescue therapy were derived from the SURPASS-2 study. Drug costs in 2022 US dollars were based on wholesale acquisition cost. Costs associated with adverse events were sourced from the published literature. One-way sensitivity analyses were conducted. RESULTS: Treatment with once-weekly tirzepatide 10 mg injection was associated with a higher cost and larger reduction in A1c and body weight after 52 weeks, compared with once-weekly semaglutide 1 mg injection. The incremental cost-effectiveness ratio for tirzepatide vs semaglutide was $2,247 per 1% reduction in A1c and $237 per 1 kg weight loss. One-way sensitivity analysis suggested that incremental cost-effectiveness ratios were most sensitive to the drug costs and treatment effect on A1c and weight. CONCLUSIONS: Once-weekly tirzepatide 10 mg was associated with higher cost and greater reduction in A1c and weight vs semaglutide. Tirzepatide 10 mg is cost-effective compared with semaglutide 1 mg if payers’ willingness-to-pay threshold exceeds $2,247 for 1% reduction in A1c level and $237 for 1 kg weight loss.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小小浪味仙完成签到,获得积分20
刚刚
琪子完成签到,获得积分20
1秒前
2秒前
FashionBoy的应助被Syanx_8采纳,获得10
2秒前
2秒前
帝休完成签到,获得积分10
3秒前
汉堡包的应助被Polymer采纳,获得10
3秒前
秋风的应助被阿玉艳采纳,获得20
4秒前
ZHW完成签到,获得积分10
4秒前
调皮颜发布了新的文献求助10
5秒前
6秒前
997完成签到,获得积分10
6秒前
hhh的应助被成就书芹采纳,获得10
7秒前
观赏热带鱼完成签到,获得积分10
8秒前
zy发布了新的文献求助10
8秒前
kkkk完成签到,获得积分10
9秒前
我是老大的应助被Lz采纳,获得10
9秒前
雨雨雨发布了新的文献求助10
9秒前
排骨焖面完成签到,获得积分10
10秒前
mikro完成签到 ,获得积分10
11秒前
11完成签到,获得积分10
11秒前
宫水三叶完成签到,获得积分20
11秒前
GTCC完成签到,获得积分10
11秒前
乐乐的应助被李优秀采纳,获得10
12秒前
13秒前
丘比特的应助被FFFFFF采纳,获得10
14秒前
成就书芹完成签到,获得积分10
15秒前
鹿鹿七完成签到 ,获得积分10
15秒前
ning10完成签到,获得积分20
15秒前
李健的小迷弟的应助被琪子采纳,获得20
15秒前
玻丽露露完成签到,获得积分10
15秒前
16秒前
16秒前
paofu完成签到,获得积分10
16秒前
情怀的应助被LFJ采纳,获得10
16秒前
17秒前
酷波er的应助被好天气采纳,获得10
18秒前
润泉完成签到,获得积分10
18秒前
搂猫睡觉的鱼完成签到,获得积分10
18秒前
田様的应助被Rony采纳,获得10
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8186480
求助须知:如何正确求助?哪些是违规求助? 9574861
关于积分的说明 21838499
捐赠科研通 7784154
什么是DOI,文献DOI怎么找? 3434775
关于科研通互助平台的介绍 2559164
邀请新用户注册赠送积分活动 2481565